Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$42.96 USD
-0.79 (-1.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $42.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Kymera Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
KYMR 42.96 -0.79(-1.81%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Other News for KYMR
Kymera Therapeutics (KYMR) Gains Support as Data Release Approaches
Kymera Therapeutics transferred with Buy rating at B. Riley
Goldman Sachs Initiates Coverage on Kymera Therapeutics (KYMR) as Early-Stage Biotech | KYMR ...
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Gilead sees Q2 EPS hit from IPR&D expenses